Neurofilament light chain: An important step toward a disease biomarker in multiple sclerosis

TY - JOUR

T1 - Neurofilament light chain

T2 - An important step toward a disease biomarker in multiple sclerosis

AU - Berger, Thomas

AU - Stuve, Olaf

N1 - Funding Information: T. Berger has served on scientific advisory boards sponsored by Biogen, Biologix, Celgene, Merck, Novartis, Ratiopharm, Roche, Sanofi Genzyme, TEVA, and TG Therapeutics; has been a consultant for Almirall, Biogen, Bionorica, Merck, Novartis, and Sanofi Genzyme; and has received research support from Alexion, Almirall, Bayer, Biogen, Merck, Novartis, Ratiopharm, Roche, Sanofi-Aventis, and TEVA. O. Stüve has served on scientific advisory boards for Pfizer, TG Therapeutics, and Genentech-Roche; has served on the editorial board of Therapeutic Advances in Neurological Disorders; has been a consultant for Celgene and EMD Serono; and has received research support from Sanofi Genzyme. Go to Neurology. org/N for full disclosures.

PY - 2019/3/5

Y1 - 2019/3/5

UR - http://www.scopus.com/inward/record.url?scp=85062419403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062419403&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000007022

DO - 10.1212/WNL.0000000000007022

M3 - Editorial

C2 - 30737335

AN - SCOPUS:85062419403

SN - 0028-3878

VL - 92

SP - 451

EP - 452

JO - Neurology

JF - Neurology

IS - 10

ER -